Tyme Technologies

November 11, 2021

The quest for efficacy in pancreatic cancer

Late-stage therapies from Fibrogen, Tyme and Novartis need to avoid the same pitfalls as Erytech and Rafael.

November 05, 2019

The late-stage pancreatic pipeline thins again as Halozyme falls

April 04, 2019

Topsy turvy times for industry’s mid and small cap stocks in the first quarter

What was up is now down as smaller biotech stocks deal with clinical trial failure and acquisitions.

January 21, 2019

Imbruvica flop puts pressure on pancreatic pipeline

January 18, 2019

Investors put Tyme in a bottle after pancreatic cancer readout